Liraglutide: difference between revisions
Diff·revision 17 → 18·07:28, 9 Apr 2025
Difference between revision 17 and revision 18 of Liraglutide. 5 lines changed; the page grew by 718 bytes.
| Revision 17 — 00:52, 24 Mar 2025 SurpassSunniva (talk) expand §Clinical evidence 4,532 bytes ±0 | Revision 18 — 07:28, 9 Apr 2025 CategoryBot (talk) bot: expand DOI to full citation 5,250 bytes +718 | ||
|---|---|---|---|
| 37 | Liraglutide is also approved for use in adolescents with type 2 diabetes and, in some jurisdictions, for adolescent obesity — a broader paediatric position than most agents in the class hold, reflecting its longer regulatory history. | 37 | Liraglutide is also approved for use in adolescents with type 2 diabetes and, in some jurisdictions, for adolescent obesity — a broader paediatric position than most agents in the class hold, reflecting its longer regulatory history. |
| 38 | 38 | ||
| + | 39 | == Practical differences from weekly agents == | |
| + | 40 | Daily dosing changes the practical profile in ways that are not captured by efficacy figures. Steady state is reached in two to three days rather than four to five weeks, so a dose change is expressed almost immediately and titration can proceed weekly rather than monthly. A missed dose matters less: the next scheduled dose simply resumes the schedule, whereas a missed weekly dose leaves a longer gap. See [[Missed dose]]. | |
| + | 41 | ||
| + | 42 | Conversely, the peak-to-trough ratio within a dosing interval is higher than for a weekly agent, and daily injection is a larger practical burden. Discontinuation rates in head-to-head comparisons have favoured weekly agents.{{r|knudsen2019}} | |
| + | 43 | ||
| 39 | == References == | 44 | == References == |
| 40 | {{reflist}} | 45 | {{reflist}} |